Combined anti-leukemic effect of gilteritinib and GSK-J4 in FLT3-ITD+ acute myeloid leukemia
Gilteritinib treats acute myeloid leukemia (AML) with the FMS-like receptor tyrosine kinase-3 (FLT3) internal tandem duplication (ITD) mutation. Dysregulation of histone modification affects the genesis and progression of AML. Strategies targeting key histone regulators have not been applied to the...
Guardat en:
| Autors principals: | , , , , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Elsevier
2025-02-01
|
| Col·lecció: | Translational Oncology |
| Matèries: | |
| Accés en línia: | http://www.sciencedirect.com/science/article/pii/S1936523325000026 |
| Etiquetes: |
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|